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For a normally distributed risk X,  
logX =Y~ N(,2) 
 
i.e. the density of Y, the logarithm of the risk, is given by: 
A standard result is that the mean of a log-normal distribution is given by: 
E[X] = E[exp(Y)] = exp(+2/2) 
E[X] = 1 
Thus 
 = -2/2 
Mean of risk score is –variance/2 
And similarly 
E[X2] = E[exp(2Y)] = exp(2+22) 
So that the variance of X is given by: 
Var(X) = exp(2+22)-exp(2+2) 
And the relative risk to twins by 
M= E[X2]/E[X]2 = exp(2) 











This is also a normal distribution with parameters (+2,2). Thus, the risk distribution in the cases 
has the same shape as in the general population but shifted (on a log-scale) by 2.  (Hence, the mean 































Supplementary Tables  
Supplementary Table 1S. Number of men 50-69 years with and with no prostate cancer by method 
of detection from each of the three studies 
Study  No. of men with 
screen-detected 
prostate cancer * 
No. of men with 
clinically-detected 
prostate cancer   
No. of men with 
no prostate 
cancer 
ProtecT 2,148  6,648 
SEARCH     398 3,701    960 
UKGPCS   867 2,290  
* The observed prevalence of screen-detected cancers were based on ProtecT PSA-detected cases 
only, as the denominator population for SEARCH and UKGPCS studies are not known.  
Screen-detection refers to detection as part of an organised PSA testing  
 
Supplementary Table 2S. Common susceptibility loci for prostate cancer included in deriving 
polygenic risk score 










OR  95% CI  
References 
1q21 rs1218582   G A 0.45 1.06 1.03 1.09 1 
1q32 rs4245739   C A 0.25 0.91 0.88 0.95 1 
2p11 rs10187424 rs1009 
0.96 
G A 0.41 0.92 0.89 0.94 
2 
2p11 rs1009 rs10187424 G A 0.43 0.91 0.94 0.89 
2p15 rs721048   A G 0.19 1.13 1.09 1.16 3 
2p21 rs1465618   A G 0.22 1.08 1.05 1.11 4 
2p24 rs13385191 rs13394027 
0.89 
G A 0.56 1.15 1.10 1.21 
5 
2p24 rs13394027 rs13385191 A G 0.22 1.05 1.01 1.08 
2p25 rs11902236   A G 0.27 1.07 1.03 1.10 1 
2q31 rs12621278   G A 0.05 0.76 0.69 0.83 4 
2q37 rs2292884   G A 0.24 1.06 1.03 1.10 2,6 
2q37 rs3771570   A G 0.15 1.12 1.08 1.16 1 
3p11 rs2055109 rs1494248 
0.78 
C T 0.90 1.20 1.13 1.29 
7 
3p11 rs1494248 rs2055109 C A 0.30 0.98 0.96 1.01 
3p12 rs2660753   A G 0.11 1.13 1.08 1.17 8 
3q13 rs7611694   C A 0.41 0.91 0.88 0.94 1 
3q21 rs10934853   A C 0.29 1.12 1.08 1.15 9 
3q23 rs6763931   A G 0.45 1.03 1.01 1.06 2 










OR  95% CI  
References 
3q26 rs10936632 rs10804839 
0.76 
C A 0.48 0.9 0.88 0.93 
2 
3q26 rs10804839 rs10936632 A T 0.45 1.09 1.06 1.12 
4q13 rs1894292   A G 0.48 0.91 0.88 0.94 1 
4q22 rs12500426   A C 0.48 1.09 1.06 1.12 4 
4q22 rs17021918   A G 0.34 0.90 0.87 0.93 4 
4q24 rs7679673   A C 0.39 0.86 0.83 0.89 4 
5p12 rs2121875 rs1482679 
1.00 
G T 0.34 1.05 1.02 1.08 
2 
5p12 rs1482679 rs2121875 G A 0.33 1.07 1.04 1.1 
5p15 rs12653946   A G 0.43 1.08 1.05 1.11 5 
5q35 rs6869841   A G 0.21 1.07 1.04 1.11 1 
6p21 rs130067   C A 0.21 1.07 1.03 1.10 2 
6p21 rs1983891 rs913074 
1.00 
T C 0.41 1.15 1.09 1.21 
5 
6p21 rs913074 rs1983891 G A 0.28 1.07 1.04 1.10 
6p21 rs2273669   G A 0.15 1.07 1.03 1.11 1 
6q25 rs1933488   G A 0.41 0.89 0.86 0.92 1 
6q25 rs9364554   A G 0.30 1.10 1.07 1.13 8 
7p15 rs10486567   A G 0.22 0.87 0.83 0.9 10 
7p21 rs12155172   A G 0.23 1.11 1.07 1.14 1 
7q21 rs6465657   G A 0.48 1.12 1.09 1.15 8 
8p21 rs11135910   A G 0.16 1.11 1.07 1.15 1 










OR  95% CI  
References 
8p21 rs1512268   A G 0.45 1.13 1.10 1.16 4 
8p21 rs2928679   A G 0.44 1.05 1.02 1.08 4 
8q24 rs10086908   G A 0.29 0.87 0.84 0.90 11 
8q24 rs12543663   C A 0.31 1.15 1.12 1.18 11 
8q24 rs1447295   A C 0.13 1.43 1.39 1.48 12 
8q24 rs16901979   A C 0.04 1.66 1.59 1.74 13 
8q24 rs620861   A G 0.35 0.87 0.84 0.90 11 
8q24 rs6983267   A C 0.49 0.8 0.78 0.83 14 
9q31 rs817826   C T 0.08 1.41 1.29 1.54 15 
9q33 rs1571801   A C 0.28 1.03 1 1.07 16 
10q11 rs10993994   A G 0.41 1.23 1.2 1.26 8,10 
10q26 rs2252004 rs2252344 
1.00 
G T 0.77 1.16 1.10 1.22 
7 
10q26 rs2252344 rs2252004 A G 0.10 0.98 0.94 1.03 
10q26 rs4962416   G A 0.27 1.05 1.02 1.08 10 
11p15 rs7127900   A G 0.21 1.24 1.21 1.28 4 
11q13 rs7931342   A C 0.48 0.83 0.80 0.86 8,10 
11q22 rs11568818   G A 0.44 0.91 0.88 0.94 1 
12q13 rs10875943   G A 0.30 1.10 1.07 1.13 2 
12q13 rs902774   A G 0.16 1.13 1.09 1.16 6 
12q24 rs1270884   A G 0.49 1.07 1.04 1.10 1 










OR  95% CI  
References 
14q22 rs8008270   A G 0.18 0.89 0.86 0.93 1 
14q24 rs7141529   G A 0.49 1.09 1.06 1.12 1 
17p13 rs684232   G A 0.36 1.10 1.07 1.13 1 
17q12 rs11649743   A G 0.19 0.88 0.84 0.92 17 
17q12 rs4430796 rs11651755 
1.00 
A G 0.49 1.22 1.15 1.3 
13 
17q12 rs11651755 rs4430796 G A 0.48 0.81 0.79 0.83 
17q21 rs11650494   A G 0.08 1.15 1.1 1.21 1 
17q24 rs1859962   A C 0.52 0.84 0.81 0.87 13 
18q23 rs7241993   A G 0.30 0.92 0.89 0.95 1 
19q13 rs103294   A G 0.22 1.00 0.97 1.04 15 
19q13 rs11672691   A G 0.26 0.9 0.87 0.93 18 
19q13 rs2735839   A G 0.13 0.83 0.79 0.88 8 
19q13 rs8102476   A G 0.46 0.93 0.9 0.96 9 
20q13 rs2427345   A G 0.37 0.94 0.91 0.97 1 
Xp11 rs5945619   G A 0.40 1.11 1.09 1.13 3,8 
Xq12 rs5919432   G A 0.19 0.96 0.94 0.99 2 
* Correlation between two proxy SNPs  
†Derived from the genotyping of 211,155 SNPs on a custom Illumina array (iCOGS) in blood from 
25,074 prostate cancer cases and 24,272 controls from the international PRACTICAL   Consortium1 
Abbreviations: A, adenine; C, cytosine; G, guanine; T, tyrosine 
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